We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

JHX:ASXJames Hardie Industries PLC Chess Units of Foreign Securities Analysis

Data as of 2026-06-17 - not real-time

A$36.03

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

James Hardie Industries (JHX) is trading at AUD 36.03, comfortably above its 20‑day SMA of 31.48 and the 200‑day SMA of 30.72, signalling short‑term strength. However, the RSI of 73.5 places the stock in overbought territory and the decreasing volume trend raises caution about the sustainability of the rally. The MACD remains bullish with the line (1.56) above the signal (1.08), yet the 40.9% 30‑day volatility and a beta near 1.0 suggest heightened price swings. Valuation metrics are stark: a trailing PE of 133 versus a forward PE of 17.5, and a DCF‑derived fair value of only AUD 15, imply the market is pricing in significant optimism. Analyst consensus is a “buy” with a median target of AUD 37.02, offering a marginal upside of less than 1% from current levels. Fundamentally, the company posted a 44.5% revenue growth year‑over‑year, but profit margins remain thin at 2.15% and ROE is just 2.4%, reflecting modest earnings power. Leverage is a concern, with a debt‑to‑equity ratio of 76 and total debt exceeding AUD 4.8 bn, dwarfing its cash balance of AUD 0.27 bn. The business is diversified across the United States, Australia, New Zealand and Europe, providing geographic breadth but also exposure to regional housing cycles. No dividend is paid, removing a cash‑flow cushion for investors. The broader market sentiment is extreme greed (FGI 92), which could amplify price volatility in the near term. Overall, the stock sits at the intersection of strong growth narratives and a markedly overvalued price, demanding careful timing for entry.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • RSI indicating overbought conditions
  • Approaching resistance near AUD 36.11
  • Decreasing volume and high short‑term volatility

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Robust 44.5% revenue growth
  • Forward PE compression to 17.5 offering valuation improvement
  • Bullish MACD and analyst buy consensus with modest upside target

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • Long‑term exposure to global housing demand
  • High leverage and low profitability limiting margin for error
  • Current price far above DCF fair value, reducing upside potential

Key Metrics & Analysis

Financial Health

Revenue Growth44.50%
Profit Margin2.15%
P/E Ratio133.4
ROE2.42%
ROA5.09%
Debt/Equity76.09
P/B Ratio2.3
Op. Cash FlowA$589.8M
Free Cash FlowA$370.0M

Technical Analysis

TrendNeutral
RSI73.5
SupportA$25.41
ResistanceA$36.11
MA 20A$31.48
MA 50A$29.95
MA 200A$30.72
MACDBullish
VolumeDecreasing
Fear & Greed Index92.13

Valuation

Fair ValueA$15.07
Target PriceA$35.73
Upside/Downside-0.85%
GradeOvervalued
TypeBlend

Risk Assessment

Beta1.01
Volatility40.91%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.